Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-05-01

Clinical Trial Update: Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 double-masked trial evaluating PG324 Ophthalmic Solution in open-angle glaucoma and ocular hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PG324 ophthalmic solution (PG324)

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2019-05-01